← All Biomarkers

BRAF

7 drugs

B-Raf Proto-Oncogene

Predictive biomarker for patient selection in 16 indications

Understanding BRAF

What it means: BRAF is a serine/threonine kinase in the MAPK signaling pathway. Mutations (most commonly V600E) cause constitutive activation.

Why it matters: BRAF inhibitors (vemurafenib, dabrafenib) combined with MEK inhibitors show strong responses in BRAF-mutant cancers.

Testing: Tested via NGS, PCR-based assays, or IHC (V600E-specific antibody). NGS detects all BRAF variants.

7

Approved Drugs

16

Indications

6

Companies

Search BRAF Clinical Trials

Search recruiting trials on ClinicalTrials.gov

Drugs Targeting BRAF

Drug	Company	Therapeutic Area
NEXAVAR	Bayer	Oncology
OJEMDA	DAY ONE BIOPHARMS	Oncology
QINLOCK	DECIPHERA PHARMS	Oncology
SORAFENIB TOSYLATE	YABAO PHARM	Oncology
STIVARGA	Bayer	Oncology
TAFINLAR	Novartis	Oncology
ZELBORAF	Roche	Oncology

Indications

Melanoma Erdheim-Chester Disease Metastatic colorectal cancer Locally advanced, unresectable or metastatic gastrointestinal stromal tumor Hepatocellular carcinoma Hepatocellular Carcinoma Renal Cell Carcinoma Thyroid Carcinoma Non-Small Cell Lung Cancer Anaplastic Thyroid Cancer Solid Tumors Gastrointestinal Stromal Tumor Low-Grade Glioma Unresectable hepatocellular carcinoma Advanced renal cell carcinoma Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment

Companies with BRAF Drugs

Roche Bayer YABAO PHARM Novartis DECIPHERA PHARMS DAY ONE BIOPHARMS